Literature DB >> 15255290

Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid.

Megumi Yoshikawa1, Yoji Ikegami, Kazumi Sano, Hisahiro Yoshida, Hideyuki Mitomo, Seigo Sawada, Toshihisa Ishikawa.   

Abstract

Irinotecan (CPT-11) is a widely-used potent anticancer drug that inhibits mammalian DNA topoisomerase I, however overexpression of the ATP-binding cassette transporter ABCG2 can confer cancer cells resistance to SN-38, the active form of CPT-11. In the present study, we have examined the contribution of three variant forms of ABCG2 to SN-38 resistance. Exogenous expression of the Arg482 (wild type), Gly482, and Thr482 variants of ABCG2 conferred HEK293 cells resistance to SN-38 by 15.0-, 5.0-, and 5.3-fold, respectively. In plasma membrane vesicles prepared from the ABCG2 variant cDNA-transfected HEK293 cells, [Arg482]ABCG2 transported SN-38 and its glucuronide conjugate in an ATP-dependent manner; however, only minimal transport activities were observed with the other variants (Gly482 and Thr482). In addition, we have screened natural flavonoids to find potent inhibitors of [Arg482]ABCG2. Quercetin was found to be the strongest inhibitor (Ki = 0.28 microM) among natural flavonoids tested in the plasma membrane system in this study. When [Arg482]ABCG2-transfected HEK293 cells were incubated with SN-38 in the presence of 20 microM quercetin, cellular resistance to SN-38 was partly reversed. In this context, certain flavonoid derivatives are considered to be good candidates for development of ABCG2 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15255290

Source DB:  PubMed          Journal:  J Exp Ther Oncol        ISSN: 1359-4117


  10 in total

1.  Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2.

Authors:  Muhammad Ali Versiani; Thushara Diyabalanage; Ranjala Ratnayake; Curtis J Henrich; Susan E Bates; James B McMahon; Kirk R Gustafson
Journal:  J Nat Prod       Date:  2011-01-28       Impact factor: 4.050

Review 2.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors:  Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

Review 3.  Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design.

Authors:  Toshihisa Ishikawa; Ai Tamura; Hikaru Saito; Kanako Wakabayashi; Hiroshi Nakagawa
Journal:  Naturwissenschaften       Date:  2005-10

Review 4.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

5.  Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?

Authors:  Fengzhi Li; Xiang Ling; Danni L Harris; Jianqun Liao; Yuping Wang; David Westover; Guohui Jiang; Bo Xu; Patrick M Boland; Chunyang Jin
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

6.  St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.

Authors:  Zeping Hu; Xiaoxia Yang; Paul Chi-Liu Ho; Eli Chan; Sui Yung Chan; Congjian Xu; Xiaotian Li; Yi-Zhun Zhu; Wei Duan; Xiao Chen; Min Huang; Hongyuan Yang; Shufeng Zhou
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

7.  FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy.

Authors:  Xiang Ling; Wenjie Wu; Ieman A M Aljahdali; Jianqun Liao; Sreevidya Santha; Christos Fountzilas; Patrick M Boland; Fengzhi Li
Journal:  Clin Transl Med       Date:  2022-05

8.  Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter.

Authors:  Chung-Pu Wu; Suneet Shukla; Anna Maria Calcagno; Matthew D Hall; Michael M Gottesman; Suresh V Ambudkar
Journal:  Mol Cancer Ther       Date:  2007-12       Impact factor: 6.261

Review 9.  Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?

Authors:  Fengzhi Li; Ieman Aljahdali; Xiang Ling
Journal:  J Exp Clin Cancer Res       Date:  2019-08-22

10.  Negligible Effect of Quercetin in the Pharmacokinetics of Sulfasalazine in Rats and Beagles: Metabolic Inactivation of the Interaction Potential of Quercetin with BCRP.

Authors:  Ju-Hee Oh; Dokeun Kim; Haejun Lee; Gyeonghee Kim; Taehoon Park; Min Chang Kim; Young-Joo Lee
Journal:  Pharmaceutics       Date:  2021-11-23       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.